AI solution will help improve patient outcomes by providing timely and accurate detection of critical abnormalities
Milton Keynes University Hospital NHS Foundation Trust (MKUH) will use Qure’s qER for automating the detection of critical and life-threatening abnormalities in head CT scans, including intracranial haemorrhages (ICH) caused by trauma, accidents or strokes.
It is an FDA cleared and EU MDR Class IIb certified solution, and will be used for all non-contrast CT scans at the Trust. The solution aids in triaging critical cases, within three minutes, in the emergency department, especially during out-of-hour shifts when a larger team may not be available.
“This is a great step forward for frontline A&E patient care and we are delighted to partner with Blackford to bring qER to Milton Keynes University Hospital,” said Darren Stephens, Senior Vice President & Commercial Head UK and Europe of Qure.ai. “Our AI solution will help improve patient outcomes by providing timely and accurate detection of critical abnormalities, enabling clinicians to make informed decisions and take appropriate actions.”
The partnership between Blackford and Qure.ai is part of an ongoing effort to leverage AI technology to enhance clinical decision-making. MKUH procured the Blackford Platform to underpin its AI strategy and make evaluation, adoption, monitoring, and support of AI more efficient. qER by Qure.ai is one of the first AI solutions to be successfully evaluated and deployed via the Blackford Platform at MKUH. By automating the detection of critical abnormalities in head CT scans, qER can help clinicians save time and focus on providing the best possible care for patients.
Blackford are pioneers in the radiology AI space, with over a decade of experience working in partnership with leading hospitals and ground-breaking technology providers. They operate as a strategic AI partner, providing access to a tried-and-tested core platform, tailored services and a portfolio of 100+ applications to help healthcare providers unlock the value of AI and improve patient outcomes. The company’s collaboration and recent arms-length acquisition by Bayer ensures that customers and partners have the support and long-term security needed to underpin successful AI strategies.